BATM Advanced Communications Ld COVID-19 test effective in diagnosing new strain (7524J)
December 24 2020 - 2:00AM
UK Regulatory
TIDMBVC
RNS Number : 7524J
BATM Advanced Communications Ld
24 December 2020
LEI: 213800FLQUB9J289RU66
24 December 2020
BATM Advanced Communications Limited
("BATM" or "the Group")
BATM confirms effectiveness of its COVID-19 test in diagnosing
new strain of virus
COVID-19 tests effective in detecting the SARS-CoV-2 variant
observed in the UK and elsewhere
BATM (LSE: BVC; TASE: BVC), a leading provider of real-time
technologies for networking solutions and medical laboratory
systems, announces that its COVID-19 kit has been tested against
the new SARS-CoV-2 variant - the virus that causes COVID-19 - that
is being observed as rapidly spreading in the UK and elsewhere and
the Group can confirm that it is effective in diagnosing this new
strain.
The new SARS-CoV-2 variant, referred to as SARS-CoV-2 VUI
202012/01, is defined by multiple spike (S) protein mutations as
well as mutations in other genomic regions. The Group, in
partnership with Tor Vergata University, continually tests its kits
against any mutation that is perceived to be clinically material to
ensure its kits are accurately able to detect all known variants of
COVID-19.
The Group's COVID-19 antigen test has 4+1 gene discovery
capability, including the S protein, compared with a market
standard of one to three gene discovery. This enables it to provide
more accurate results, reducing the risk of false positives and
false negatives. The Group is now offering its 4+1 kit as its
standard COVID-19 antigen test, which is being delivered to several
private and government customers in Europe and other
geographies.
Dr Zvi Marom, CEO of BATM, said: "I am pleased to confirm that
our COVID-19 tests are effective in accurately detecting all
COVID-19 variants, including in those infected with this latest
mutation. Viruses constantly change through mutation and our
diagnostics platform has been built on our recognition that we must
always think of the future. As a result, we were able to rapidly
develop COVID-19 tests in response to the outbreak and those kits
have been designed to be effective against the emergence of new
variants."
Enquiries:
BATM Advanced Communications
Dr Zvi Marom, Chief Executive Officer +972 9866 2525
Moti Nagar, Chief Financial Officer
Shore Capital
Mark Percy, Anita Ghanekar, James Thomas (Corporate Advisory)
Henry Willcocks (Corporate Broking) +44 20 7408 4050
Luther Pendragon
Harry Chathli, Claire Norbury +44 20 7618 9100
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RESBIBDDIUDDGGX
(END) Dow Jones Newswires
December 24, 2020 02:00 ET (07:00 GMT)
Batm Advanced Communicat... (LSE:BVC)
Historical Stock Chart
From Apr 2024 to May 2024
Batm Advanced Communicat... (LSE:BVC)
Historical Stock Chart
From May 2023 to May 2024